Enlivex Snags a $21M Loan: Because Even Biotech Needs a DeFi-Style Treasury Buffer
Enlivex, a biotech firm betting big on the ultimate alpha play—not dying—has just locked down a $21 million debt raise. It seems even companies chasing the fountain of youth need a liquidity pool for a rainy day.
The fresh capital is earmarked to bolster the company's treasury ops, because what's a cutting-edge science venture without a robust, well-managed war chest? You can't very well disrupt mortality if you're worried about your runway, now can you?
Share Article
Quick Info
Disclaimer: This content is for information and entertainment purposes only. It does not constitute financial, investment, legal, or tax advice. Always do your own research and consult with qualified professionals before making any financial decisions.
See our Terms of Service, Privacy Policy, and Editorial Policy.